drugset
drugset / Trial / NCT00080015

Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)

NCT00080015 ↗

Phase 2 Completed 9 enrolled Ipsen
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase II, open-label, multicenter, single-arm, exploratory "proof of concept" study. Diflomotecan (7 mg fixed dose) will be administered as a 20-minute IV infusion once every 3 weeks in patients with sensitive small cell lung cancer (SCLC) with progressive disease after first-line treatment with a platinum-based regimen.

Timeline

Start
2004-03-12
Primary completion
2005-02
Completion
2005-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Diflomotecan Small molecule 7 mg Intravenous

Indications

small cell lung carcinoma